Page 13 - Liminal Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Equities research analysts predict that Liminal BioSciences Inc. (NASDAQ:LMNL – Get Rating) will post earnings per share of ($0.16) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Liminal BioSciences’ earnings. Liminal BioSciences posted earnings of ($0.52) per share in the same quarter last year, which indicates a […]

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provides an update on plans for the further development...